INVESTIGATION OF THE CLINICAL SIGNIFICANCE OF ESCITALOPRAM-INDUCED ELECTROCARDIOGRAPHIC CHANGES IN MEN: A PILOT OBSERVATIONAL STUDY

  • Ahmad Abdulrahman Almeman Department of Pharmacology, College of Medicine, Qassim University, Qassim, Saudi Arabia
  • ANAS ALTWIJRI Department of Pharmacology, College of Medicine, Qassim University, Qassim, Saudi Arabia
  • EBRAHIM ALSAIF Department of Pharmacology, College of Medicine, Qassim University, Qassim, Saudi Arabia
  • RAKAN ALAHMAD Department of Pharmacology, College of Medicine, Qassim University, Qassim, Saudi Arabia
  • RAKAN ALAHMAD Department of Pharmacology, College of Medicine, Qassim University, Qassim, Saudi Arabia
  • AZZAM ALYAHYA Department of Pharmacology, College of Medicine, Qassim University, Qassim, Saudi Arabia
  • NABIL ALRUWAIS Department of Psychiatry, Mental Hospital Buraydah, Qassim, Saudi Arabia
  • BASEM ALMOGBEL Department of Psychiatry, Mental Hospital Buraydah, Qassim, Saudi Arabia
  • AKRAM ELDESOKY Department of Interventional Cardiology, Prince Sultan Cardiac Center, Qassim, Saudi Arabia

Abstract

Objective: We sought to investigate the clinical significance of secondary electrocardiographic (ECG) changes in men after using escitalopram.


Methods: This pilot observational cohort study recruited male patients taking escitalopram for at least 6 mo in Mental Hospital of Qassim. All patients underwent a 12-lead ECG examination. We also measured the heart rate (HR), QTc, and QRS interval. Data on all related medical conditions and medications were recorded.


Results: Fifty-three men were recruited, with a mean age of 37.39±8.39 y: 34.4% and 31.1% of these patients were taking escitalopram for depression and anxiety, respectively. The mean dose of escitalopram was 14.35 mg. Observations showed that 20.9% of the patients taking escitalopram had a fast HR (>100 beats/min [bpm]), indicative of sinus tachycardia, whereas 11.4% of patients had a slow HR (<60 bpm). The mean QT and QTc in patients taking escitalopram were 366.62±28.69 and 398.92±16.15 ms, respectively.


Conclusion: Low doses of escitalopram resulted in minimal clinically significant changes. Thus, patients should be monitored when doses are escalated further.

Keywords: Selective serotonin reuptake inhibitors, Anxiety disorders, Electrocardiography, Corrected QT, Heart rate, Tachycardia, Depression

Downloads

Download data is not yet available.

Author Biography

Ahmad Abdulrahman Almeman, Department of Pharmacology, College of Medicine, Qassim University, Qassim, Saudi Arabia

Director of Research center college of medcine, Qassim University, Qassim, Saudi Arabia

coordinator of the anticoagulation clinic, Prince Sultan Cardiac Center, Buriadah, Qassim

References

1. Søgaard B, Mengel H, Rao N, Larsen F. The pharmacokinetics of escitalopram after oral and intravenous administration of single and multiple doses to healthy subjects. J Clin Pharmacol 2005;45:1400-6.
2. US Food Drug Administration. Lexapro tablet; 2004. Available from: https://www.fda.gov/ohrms/dockets/ac/04/briefing/2004-4065b1-22-tab11C-Lexapro-Tabs-SLR015.pdf. [Last accessed on 14 Mar 2018]
3. Rao N. The clinical pharmacokinetics of escitalopram. Clin Pharmacokinet 2007;46:281-90.
4. US Food Drug Administration (FDA). Clinical Evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. Silver spring: center for drug evaluation and research and center for biologics evaluation and research; 2005. p. E14.
5. Yuksel FV, Tuzer V, Goka E. Escitalopram intoxication. Eur Psychiatry 2005;20:82.
6. Van Gorp F, Whyte IM, Isbister GK. Clinical and ECG effects of escitalopram overdose. Ann Emerg Med 2009;54:404-8.
7. Tseng PT, Lee Y, Lin YE, Lin PY. Low-dose escitalopram for 2 d associated with corrected QT interval prolongation in a middle-aged woman: a case report and literature review. Gen Hosp Psychiatry 2012;34:210. e13-5.
8. Funk KA, Bostwick JR. A comparison of the risk of QT prolongation among SSRIs. Ann Pharmacother 2013;47:1330-41.
9. U. S. Food and Drug Administration. FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses; 2012. http://www.fda.gov/Drugs/DrugSafety/ucm297391.htm. [Last accessed on 10 Sep 2012]
10. Howland RH. A question about the potential cardiac toxicity of escitalopram. J Psychosoc Nurs Ment Health Serv 2012;50:17-20.
11. Beach SR, Kostis WJ, Celano CM, Januzzi JL, Ruskin JN, Noseworthy PA, et al. Meta-analysis of selective serotonin reuptake inhibitor-associated QTc prolongation. J Clin Psychiatry 2014;75:e441-9.
12. Keller DL. Prescribe escitalopram instead of citalopram. Am J Med 2013;126:e21.
13. Scharko AM, Schumacher J. Prolonged QTc interval in a 14 y old girl with escitalopram overdose. J Child Adolesc Psychopharmacol 2008;18:297-8.
14. Medicines and Healthcare products Regulatory Agency. Citalopram and escitalopram: QT interval prolongation-new maximum daily dose restrictions (including in elderly patients), contraindications, and warnings. Drug Safety 2011;5:A1.
15. Snitker S, Doerfler RM, Soliman EZ, Deor R, St Peter WL, Kramlik S, et al. Association of QT-prolonging medication use in CKD with electrocardiographic manifestations. Clin J Am Soc Nephrol 2017;9:pii: CJN.12991216.
16. Maljuric MN, Noordam R, Aarts N, Niemeijer MN, Van den Berg ME, Hofman A, et al. Use of selective serotonin re-uptake inhibitors and the heart rate corrected QT interval in a real-life setting: the population-based rotterdam study. Br J Clin Pharmacol 2015;80:698-705.
17. Carceller Sindreu M, de Diego Adelino J, Portella MJ, Garvia Moll X, Figueras M, Fernandez Vidal A, et al. Lack of relationship between plasma levels of escitalopram and QTc-interval length. Eur Arch Psychiatry Clin Neurosci 2017;267:815-22.
18. Hasnain M, Howland RH, Vieweg WV. Escitalopram and QTc prolongation. J Psychiatry Neurosci 2013;38:E11.
19. Chattar KB, Karve AA, Subramanyam AA, Tondare SB. Prescription pattern analysis of antidepressants in psychiatric outpatient department of tertiary care hospital in India. Asian J Pharm Clin Res 2016;9:77-9.
20. Mishra S, Swain T, Mohanty M. Patterns of prescription and efficacy evaluation of antidepressants in a tertiary care teaching hospital in Eastern India. Asian J Pharm Clin Res 2012;5:193-6.
21. Wozniak G, Toska A, Saridi M, Mouzas O. Serotonin reuptake inhibitor antidepressants (SSRIs) against atherosclerosis. Med Sci Monit 2011;17:RA205-14.
22. Angermann CE, Gelbrich G, Stork S, Fallgatter A, Deckert J, Faller H, et al. Rationale and design of a randomised, controlled, multicenter trial investigating the effects of selective serotonin re-uptake inhibition on morbidity, mortality and mood in depressed heart failure patients (MOOD-HF). Eur J Heart Fail 2007;9:1212-22.
23. Thase ME, Larsen KG, Reines E, Kennedy SH. The cardiovascular safety profile of escitalopram. Eur Neuropsychopharmacol 2013;23:1391-400.
24. Yevtushenko VY, Belous AI, Yevtushenko YG, Gusinin SE, Buzik OJ, Agibalova TV. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients. Clin Ther 2007;29:2319-32.
25. Taylor D. Antidepressant drugs and cardiovascular pathology: a clinical overview of effectiveness and safety. Acta Psychiatr Scand 2008;118:434-42.
26. Schreffler SM, Marraffa JM, Stork CM, Mackey J. Sodium channel blockade with QRS widening after an escitalopram overdose. Pediatr Emerg Care 2013;29:998-1001.
27. Tampi RR, Balderas M, Carter KV, Tampi DJ, Moca M, Knudsen A, et al. Citalopram, QTc prolongation, and torsades de pointes. Psychosomatics 2015;56:36-43.
Statistics
289 Views | 93 Downloads
How to Cite
Almeman, A. A., A. ALTWIJRI, E. ALSAIF, R. ALAHMAD, R. ALAHMAD, A. ALYAHYA, N. ALRUWAIS, B. ALMOGBEL, and A. ELDESOKY. “INVESTIGATION OF THE CLINICAL SIGNIFICANCE OF ESCITALOPRAM-INDUCED ELECTROCARDIOGRAPHIC CHANGES IN MEN: A PILOT OBSERVATIONAL STUDY”. International Journal of Pharmacy and Pharmaceutical Sciences, Vol. 11, no. 4, Feb. 2019, pp. 23-25, doi:10.22159/ijpps.2019v11i4.31449.
Section
Original Article(s)